Steven R. Hagen, Ph.D. has been promoted to senior vice president of pharmaceutical development and manufacturing at AMRI. He will continue to report to chairman, president and chief executive officer Thomas E. D’Ambra, Ph.D. Dr. Hagen is responsible for approximately two-thirds of AMRI’s contract operations, including Chemical Development, Analytical and Pharmaceutical Quality Services, Small Scale cGMP Manufacturing of active ingredients and dosage forms, and Large Scale Commercial Manufacturing. These operations encompass facilities located in Albany, Rensselaer and Syracuse, NY; Burlington, MA; Holywell, Wales (UK) and Hyderabad and Aurangabad, India.

Dr. D’Ambra remarked, “Under Dr. Hagen’s leadership, AMRI has experienced growth within key sectors of AMRI’s business. Additionally, Dr. Hagen has overseen the continued expansion and adherence to world class compliance programs and milestones, as well as the consistent attainment of operating performance metrics in AMRI’s manufacturing area.”

Dr. Hagen joined AMRI in 2005 as senior director of analytical quality services and has risen to positions of increasing responsibility. In 2006, he was promoted to vice president for quality and analytical chemistry and was responsible for Analytical Chemistry, Quality Assurance and Regulatory Affairs for all AMRI locations. In 2008, Dr. Hagen was promoted to vice president of pharmaceutical development and manufacturing.

Prior to AMRI, he spent more than 10 years at Pfizer in positions of increasing responsibility culminating in director of analytical research and development at Pfizer’s Global R&D division. Before Pfizer, he managed the analytical activities at Ribi ImmunoChem Research in support of R&D, production and quality control.